The Abbott Tendyne Transcatheter Mitral Valve Implantation (TMVI)system received the European CE mark. It is the first transcatheter mitral valve replacement (TMVR) technology in the world. Aim: The main aim is to make critical need to eliminate mitral regurgitation when surgery or mitral repair is not an option in high-risk surgical patients. Abbott: Abbott is developing a transcatheter mitral valve to open-heart surgery. Building upon its success with the MitraClip device and many years of mitral valve experience and clinical evidence.
World’s First Transcatheter Mitral Valve Approved in Europe
Current Affairs Calender